- Home
- ENTA vs CGTX Comparison
ENTA vs CGTX Comparison
Compare ENTA & CGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ENTA
- CGTX
- Stock Information
- Founded
- ENTA 1995
- CGTX 2007
- Country
- ENTA United States
- CGTX United States
- Employees
- ENTA N/A
- CGTX N/A
- Industry
- ENTA Biotechnology: Pharmaceutical Preparations
- CGTX Biotechnology: Pharmaceutical Preparations
- Sector
- ENTA Health Care
- CGTX Health Care
- Exchange
- ENTA Nasdaq
- CGTX Nasdaq
- Market Cap
- ENTA 164.6M
- CGTX 158.8M
- IPO Year
- ENTA 2013
- CGTX 2021
- Fundamental
- Price
- ENTA $10.85
- CGTX $1.57
- Analyst Decision
- ENTA Strong Buy
- CGTX Strong Buy
- Analyst Count
- ENTA 5
- CGTX 3
- Target Price
- ENTA $21.00
- CGTX $2.83
- AVG Volume (30 Days)
- ENTA 554.0K
- CGTX 1.8M
- Earning Date
- ENTA 11-24-2025
- CGTX 11-07-2025
- Dividend Yield
- ENTA N/A
- CGTX N/A
- EPS Growth
- ENTA N/A
- CGTX N/A
- EPS
- ENTA N/A
- CGTX N/A
- Revenue
- ENTA $64,806,000.00
- CGTX N/A
- Revenue This Year
- ENTA $0.07
- CGTX N/A
- Revenue Next Year
- ENTA N/A
- CGTX N/A
- P/E Ratio
- ENTA N/A
- CGTX N/A
- Revenue Growth
- ENTA N/A
- CGTX N/A
- 52 Week Low
- ENTA $4.09
- CGTX $0.22
- 52 Week High
- ENTA $15.34
- CGTX $3.83
- Technical
- Relative Strength Index (RSI)
- ENTA 51.27
- CGTX 44.00
- Support Level
- ENTA $10.30
- CGTX $1.53
- Resistance Level
- ENTA $11.15
- CGTX $1.78
- Average True Range (ATR)
- ENTA 0.56
- CGTX 0.13
- MACD
- ENTA -0.17
- CGTX -0.03
- Stochastic Oscillator
- ENTA 19.19
- CGTX 4.26
About ENTA Enanta Pharmaceuticals Inc.
Enanta Pharmaceuticals Inc is an American biotechnology company which uses robust, chemistry-driven approach and drug discovery capabilities to focus on the research and development of molecule drugs to cure viral infections and liver diseases. Uses virology and immunology method for curing the diseases. The targeted diseases are hepatitis C, hepatitis B, nonalcoholic steatohepatitis, and the respiratory syncytial virus. The novelty of company research is a specific direct-acting antiviral inhibitor against the hepatitis C virus. The company's inhibitors have been developed in collaboration with AbbVie. AbbVie markets the protease inhibitor, paritaprevir, while other inhibitors are in the pipeline.
About CGTX Cognition Therapeutics Inc.
Cognition Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of, small-molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its product candidate CT1812, is an orally delivered, small-molecule antagonist designed to penetrate the blood-brain barrier and bind selectively to the S2R complex.